Development and characterization of HBsAg-loaded Eudragit nanoparticles for effective colonic immunization

Pharmaceutical Development and Technology
Kantrol Kumar Sahu, Ravi Shankar Pandey

Abstract

The present study was undertaken with an aim to investigate the potential of targeting colonic mucosa following oral vaccine delivery to generate prophylactic humoral and mucosal immune response. In present study, response surface methodology (RSM) using the central composite design (CCD) was applied for optimization of process and composition to get uniform, stable reproducible eudragit nanoparticles suitable for targeting to colon. The optimized formulation had the composition of 173 μg HBsAg, 250 mg polymers concentration (4:1 combination of Eudragit S-100 and L-100) and 2% w/v Polyvinyl alcohol (PVA) along with adjuvant Monophosphoryl lipid A (MPLA). Mean particle size of optimized nanoparticles was found to be 730.4 nm, entrapment efficiency (58.38%) and polydispersity index of 0.185. Fluorescent spectroscopy, differential scanning calorimetry, and antigen integrity by SDS-PAGE established that antigen structure was preserved during and after formulation development. In-vitro release studies in different intestinal pH concluded antigen release at mild alkaline conditions. Real time fluorescence animal imaging confirmed the effective absorption and distribution of NPs at colon resulted in improved immune response. Present s...Continue Reading

References

Mar 1, 1991·Molecular Immunology·J H EldridgeR M Gilley
Jun 5, 1998·Journal of Chromatography. B, Biomedical Sciences and Applications·D Tleugabulova
Mar 4, 1999·Journal of Controlled Release : Official Journal of the Controlled Release Society·M Z KhanN Kurjaković
Dec 16, 2005·AAPS PharmSciTech·Deepti JainDipak K Majumdar
Jun 7, 2006·Epidemiologic Reviews·Colin W ShepardBeth P Bell
Dec 18, 2007·Neoplasia : an International Journal for Oncology Research·Wellington PhamJohn C Gore
Aug 20, 2009·Journal of Pharmaceutical Sciences·Christiane DamgéPhilippe Maincent
Sep 16, 2009·Current Pharmaceutical Biotechnology·R S Pandey, V K Dixit
Oct 20, 2009·International Journal of Pharmaceutics·Anshuman ShuklaSuresh P Vyas
Dec 5, 2009·Journal of Drug Targeting·R S Pandey, V K Dixit
Dec 17, 2009·International Journal of Pharmaceutics·Arvind K JainSuresh P Vyas
May 26, 2011·International Immunopharmacology·Chetan MaheshwariV K Dixit
May 25, 2013·Journal of Controlled Release : Official Journal of the Controlled Release Society·Er-Yuan ChuangHsing-Wen Sung
Jul 31, 2013·Journal of Clinical Virology : the Official Publication of the Pan American Society for Clinical Virology·Angelique P A VermeirenNicole H T M Dukers-Muijrers
Oct 9, 2013·Critical Reviews in Therapeutic Drug Carrier Systems·Vinod Kumar SharmaVandana Soni
Aug 16, 2016·International Immunopharmacology·Kantrol Kumar Sahu, Ravi Shankar Pandey
Mar 8, 2017·ACS Applied Materials & Interfaces·Chan YuXiangliang Yang
Apr 11, 2017·International Journal of Nanomedicine·Rana Ihab RedaAmal Hassan El-Kamel

❮ Previous
Next ❯

Citations

Mar 11, 2020·Molecules : a Journal of Synthetic Chemistry and Natural Product Chemistry·Sarah L Perry, David Julian McClements
Feb 20, 2021·Molecular Pharmaceutics·Brianna CoteAdam W G Alani

❮ Previous
Next ❯

Related Concepts

Related Feeds

Avian Influenza: Innate Immune Adjuvant

Adjuvants systems that are added to vaccines against avian influenza have be explored to enhance the innate immune system response against the virus. Here is the latest research on avian influenza and the innate immune adjuvant.

Avian Influenza: Innate Immune Adjuvant (ASM)

Adjuvants systems that are added to vaccines against avian influenza have be explored to enhance the innate immune system response against the virus. Here is the latest research on avian influenza and the innate immune adjuvant.